Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences. By Andrew Jacobs from NYT Health https://ift.tt/3o6rIvB